Table 4 Patient’s age at radiotherapy, time of radiotherapy within the disease course of metastatic breast cancer and survival after radiotherapy during the palliative situation
From: Radiotherapy in patients with distant metastatic breast cancer
Metastatic sites: | A. All cases | B. Bone | C. Brain | D. Local recurrence (incl. lymph nodes) |
|---|---|---|---|---|
255 series (%) | 161 series (%) | 57 series (%) | ||
22 series (%) | ||||
Age (years) | ||||
Mean/median | 60.6/60 | 60.5/58 | 55.4/57 | 62.6/64.5 |
(range) | (32-89) | (37-89) | (32-80) | (39-86) |
Phase of DMD | ||||
First third | 127 (49.8) | 88 (54.7) | 16 (28.1) | 15 (68.2) |
Second third | 44 (17.3) | 26 (16.1) | 15 (26.3) | 2 (9.1) |
Last third | 84 (32.8) | 47 (29.2) | 26 (45.6) | 5 (22.7) |
Series performed during: | ||||
Last 12 months of life | 135 (52.9) | 78 (48.4) | 44 (77.2) | 8 (36.4) |
Last 6 months of life | 95 (37.3) | 53 (32.9) | 33 (57.9) | 5 (22.7) |
Last month of life | 29 (11.4) | 15 (9.3) | 10 (17.5) | 2 (9.1) |
Survival after radiotherapy (months) | ||||
Mean/median | 17.8/10 | 18.9/14 | 7.6/5 | 23.2/21 |
(range) | (0.2-123) | (0.2-121) | (0.2-29) | (0.5-99) |
Survival, p-values: | ||||
A vs. B: 0.318 | B vs. C: <0.001 | |||
A vs. C: <0.001 | B vs. D: 0.346 | |||
A vs. D: 0.158 | C vs. D: <0.001 | |||